ESR1 and breast cancer: Overall, TILs and PD-L1 more effectively predict pCR in low-ER BC, but these prognostic markers showed little predictive outcome for the rest of the ER+ population, indicating that new predictive biomarkers need to be identified for the HR+/HER2− subtype.